QQ客服 官方微博 反馈留言

	Elevated High Sensitivity Troponin T (HsTnT) during Front-Line Therapy with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone plus /- Rituximab (CHOP plus /-R) or Cyclophosphamide, Epirubicin, Vincristine and Prednisone plus /- Rituximab (CEpOP plus /-R) Correlates with a Decline in Left Ventricular Ejection Fraction (LVEF) in Patients with Aggressive B-Cell Lymphoma: Results from a Randomized Prospective Clinical Trial NCT00854568
	Xue, Kai; Gu, Juan J.; Zhang, Qunling; Liu, Xiaojian; Wang, Jiachen; Luo, Jianfeng; Hernandez-Ilizaliturri, Francisco J.; Fernandez, Stanley F.; Czuczman, Myron S.; Cao, Junning
	2014
卷号	124
期号	21
会议录	BLOOD
语种	英语
URL标识	查看原文
ISSN号	0006-4971
内容类型	会议论文
URI标识	http://www.corc.org.cn/handle/1471x/4883455
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Xue, Kai,Gu, Juan J.,Zhang, Qunling,et al. Elevated High Sensitivity Troponin T (HsTnT) during Front-Line Therapy with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone plus /- Rituximab (CHOP plus /-R) or Cyclophosphamide, Epirubicin, Vincristine and Prednisone plus /- Rituximab (CEpOP plus /-R) Correlates with a Decline in Left Ventricular Ejection Fraction (LVEF) in Patients with Aggressive B-Cell Lymphoma: Results from a Randomized Prospective Clinical Trial NCT00854568[C]. 见:.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。